All posts by: Michael Zand

Stem cell reprogramming factor controls change in cellular energy generation – EurekAlert (press release)

EurekAlert (press release)Stem cell reprogramming factor controls change in cellular energy generationEurekAlert (press release)Tsukuba, Japan – A little over 10 years ago, the first reprogramming of adult cells into undifferentiated stem cells was ach… Continue reading

Stem cell reprogramming factor shown to control key metabolic change – Drug Target Review

Drug Target ReviewStem cell reprogramming factor shown to control key metabolic changeDrug Target ReviewThe stem cell reprogramming factor KL4 has been shown to control a metabolic change that explains how cells turn back the developmental clock from a… Continue reading

Global Comprehensive Synthetic Biology Markets Report 2017: Market Reached Nearly $3.9 Billion in 2016 and … – Yahoo Finance

Global Comprehensive Synthetic Biology Markets Report 2017: Market Reached Nearly $3.9 Billion in 2016 and …Yahoo FinanceWe analyze key synthetic-biology technologies and products to determine present and future market status, and forecasted growth f… Continue reading

Global Comprehensive Synthetic Biology Markets Report 2017: Market Reached Nearly $3.9 Billion in 2016 and … – GlobeNewswire (press release)

Global Comprehensive Synthetic Biology Markets Report 2017: Market Reached Nearly $3.9 Billion in 2016 and …GlobeNewswire (press release)Emerging markets including synthetic genes, synthetic-biology-enabled drugs and vaccines, genome-edited crops, ch… Continue reading

LifeCell launches community stem cell banking – India Today

CAR-T Competition Heats Up with a New IND Approval – Labiotech.eu (blog)

CAR-T Competition Heats Up with a New IND ApprovalLabiotech.eu (blog)The FDA has cleared an IND application to Servier to set sail in clinical development of UCART19, an allogeneic CAR-T cell therapy developed by Cellectis. The French company Cellectis… Continue reading

CAR-T Competition Heats Up with a New IND Approval – Labiotech.eu (blog)

Endpoints NewsCAR-T Competition Heats Up with a New IND ApprovalLabiotech.eu (blog)The FDA has cleared an IND application to Servier to set sail in clinical development of UCART19, an allogeneic CAR-T cell therapy developed by Cellectis. The French com… Continue reading